Relevance: GS II (International Relations) & GS III (Economy/Health) | Source: The Indian Express
1. The Context: Cheaper Care vs. Domestic Industry
The proposed India-EU Free Trade Agreement (FTA) is set to reshape India’s healthcare landscape.
- The Trade-off: The deal aims to slash import duties on European pharmaceuticals and medical devices.
- The Benefit: For patients, this is good news. High-end machinery (like MRIs, CT scanners) and specialized drugs—mostly imported from the EU—will become cheaper as tariffs (currently up to 11%) are removed.
- The Risk: India currently imports 80% of its medical devices. Experts fear that removing duties will flood the market with EU products, crushing nascent Indian manufacturers who are trying to grow under “Atmanirbhar Bharat”.
2. The “Data Exclusivity” Battle
The biggest friction point is Intellectual Property (IP).
- The EU Demand: The EU wants “Data Exclusivity”. This goes beyond normal patents. It demands that for a certain period (e.g., 6 years), Indian generic companies cannot rely on the clinical trial data of the original drug maker to get approval. They must generate their own data.
- India’s Stand: India rejects this because generating new data is expensive and unethical (repeating tests on humans). Accepting this would delay the launch of cheap generic medicines, threatening India’s title as the “Pharmacy of the World.”
3. The Regulatory Gap
A major hurdle for Indian exports is quality perception.
- While India exports billions in drugs, its domestic regulation of medical devices is weak. Most devices are still governed under the Drugs and Cosmetics Act, 1940, which treats complex machines like “drugs,” leading to inefficient oversight compared to the strict EU Medical Device Regulations (MDR).
UPSC Value Box
| Concept / Law | Relevance for Prelims |
| Data Exclusivity | An IP right that prevents generic drug makers from using the innovator’s clinical trial data to prove safety/efficacy. It effectively extends a monopoly even after a patent expires or if there is no patent. |
| CDSCO | Central Drugs Standard Control Organisation. Under the Ministry of Health, it is the Central Licensing Authority responsible for approving drugs and regulating medical devices in India. |
| Evergreening | A strategy used by pharma giants to extend their patent monopoly by making minor changes to an existing drug. Section 3(d) of the Indian Patent Act prevents this. |
Q. With reference to Intellectual Property Rights (IPR) in the pharmaceutical sector, the term “Data Exclusivity” refers to:
- The right of a patent holder to prevent others from manufacturing the drug for 20 years.
- A provision that prevents generic manufacturers from using the clinical trial data of the originator company for regulatory approval.
- The exclusive right of the government to access patient health data for public policy.
- A compulsory license granted to a domestic firm to manufacture a patented drug during a health emergency.
Share This Story, Choose Your Platform!
Start Yours at Ajmal IAS – with Mentorship StrategyDisciplineClarityResults that Drives Success
Your dream deserves this moment — begin it here.